Corrigendum: JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition(J Clin Invest. (2018) 128:2 (789–804) DOI: 10.1172/JCI94516)

Anna Sophia McKenney, Allison N. Lau, Amritha Varshini Hanasoge Somasundara, Barbara Spitzer, Andrew M. Intlekofer, Jihae Ahn, Kaitlyn Shank, Franck T. Rapaport, Minal A. Patel, Efthymia Papalexi, Alan H. Shih, April Chiu, Elizaveta Freinkman, Esra A. Akbay, Mya Steadman, Raj Nagaraja, Katharine Yen, Julie Teruya-Feldstein, Kwok Kin Wong, Raajit RampalMatthew G. Vander Heiden, Craig B. Thompson, Ross L. Levine

Research output: Contribution to journalComment/debate

2 Scopus citations

Abstract

Craig B. Thompson's conflict-of-interest statement was not included in the manuscript. The authors apologize for the oversight. The correct statement is below. CBT is a founder of Agios Pharmaceuticals and a member of its scientific advisory board. He also serves on the board of directors of Merck and Charles River Laboratories.

Original languageEnglish (US)
Number of pages1
JournalJournal of Clinical Investigation
Volume128
Issue number10
DOIs
StatePublished - Oct 1 2018

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Corrigendum: JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition(J Clin Invest. (2018) 128:2 (789–804) DOI: 10.1172/JCI94516)'. Together they form a unique fingerprint.

  • Cite this

    McKenney, A. S., Lau, A. N., Somasundara, A. V. H., Spitzer, B., Intlekofer, A. M., Ahn, J., Shank, K., Rapaport, F. T., Patel, M. A., Papalexi, E., Shih, A. H., Chiu, A., Freinkman, E., Akbay, E. A., Steadman, M., Nagaraja, R., Yen, K., Teruya-Feldstein, J., Wong, K. K., ... Levine, R. L. (2018). Corrigendum: JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition(J Clin Invest. (2018) 128:2 (789–804) DOI: 10.1172/JCI94516). Journal of Clinical Investigation, 128(10). https://doi.org/10.1172/JCI124920